drugset / Trial / NCT00874172

Effectiveness of New Analgesic Strategy Compared to the Usal Antalgic Strategy

NCT00874172

RandomizedParallel-groupOpen-labelTreatment

Summary

Quality of life of adult patients with sickle cell disease is deeply impaired by severe adverse medical events that inadvertently occur throughout their time life. Indeed, patients not presenting a life threatening condition often present to the emergency department with sickle cell disease crisis related pain. Currently, the effectiveness of specific analgesic strategies for treating sickle cell disease crisis related pain are mostly based on acetaminophen and opioid derivates combination along with oxygen delivery. Those strategies are effective but may last up to half an hour to obtain pain relief. This delay mostly depends on the availability of venous access and on individual patient response to treatment. Nitrous oxide is a volatile efficient analgesic therapy that has been repeatedly shown to allow rapid analgesia in the emergency department setting. The investigators hypothesise that a new analgesic strategy (rapid optimized analgesic strategy) including nitrous oxide and nefopam would be as safe and more rapidly effective than current analgesic strategy.

Timeline

Start
2009-10
Primary completion
2012-10
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Morphine Other / unclassified 3 mg Intravenous
Subject Morphine Other / unclassified 10 mg Intravenous
Subject Nefopam Small molecule 20 mg Oral
Subject Nitrous Oxide Other / unclassified Inhaled
Background Acetaminophen Small molecule 1 g Oral
Background Oxygen Other / unclassified Inhaled

Indications